HEARTCARE-B (06609) announces that the expected income for the year 2025 is approximately 4 billion to 4.1 billion yuan, an year-on-year increase of at least 43.9%.

HEARTCARE-B (06609) announced that the group is expected to achieve revenue of approximately RMB 400 million to RMB 410 million for the year ending December 31, 2025 (reporting period), an increase of at least 43.9% compared to the revenue of RMB 278 million for the year ending December 31, 2024. The group also expects to achieve a pre-tax profit of approximately RMB 80 million for the reporting period, a significant increase compared to the pre-tax net loss of RMB 12 million for the year ending December 31, 2024. The revenue growth is being driven by the following factors: the introduction of new products and technologies for ischemic stroke and an increase in market share for ischemic stroke products; the commercialization of intracranial stents and an increase in sales of other hemorrhagic stroke products; and sustained growth in sales of interventional pathway products. The group has also reduced its expense ratio through effective cost control measures for sales costs and administrative expenses.